Besic, Nikola <br/><br/>
Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma.  [electronic resource] 

 -  BMC research notes  Oct 2013 
 - 416 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1756-0500 
<br/><br/><label>Standard No.: </label>10.1186/1756-0500-6-416  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Blood Glucose--metabolism<br/>Body Mass Index<br/>Breast Neoplasms--complications<br/>Diabetes Mellitus, Type 1--complications<br/>Diabetes Mellitus, Type 2--complications<br/>Female<br/>Gene Expression<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Insulin Glargine<br/>Insulin, Long-Acting--therapeutic use<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Staging<br/>Receptor, ErbB-2--genetics